Literature DB >> 6732220

Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens.

L J Goodman, R M Fliegelman, G M Trenholme, R L Kaplan.   

Abstract

A comparison was made of the in vitro activity of ciprofloxacin (Bay o 9867) with nine other antibiotics against isolates of Campylobacter jejuni, Salmonella spp., Shigella spp., Yersinia enterocolitica, Clostridium difficile, Vibrio spp., and Escherichia coli. Minimum inhibitory concentrations of ciprofloxacin were the lowest of any compound tested for all organisms except C. difficile.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6732220      PMCID： PMC185564          DOI： 10.1128/AAC.25.4.504

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  4 in total

1.  Hippurate hydrolysis by Campylobacter fetus.

Authors:  S M Harvey
Journal:  J Clin Microbiol       Date:  1980-04       Impact factor: 5.948

2.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

3.  Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens.

Authors:  J R Carlson; S A Thornton; H L DuPont; A H West; J J Mathewson
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

4.  In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.

Authors:  D L Shungu; E Weinberg; H H Gadebusch
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191
  4 in total
  30 in total

Review 1.  Mechanisms of antibiotic resistance in Campylobacter species.

Authors:  D E Taylor; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

2.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

3.  Comparative activity of ciprofloxacin against anaerobic bacteria.

Authors:  V L Sutter; Y Y Kwok; J Bulkacz
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

Review 4.  Therapy of patients with resistant bacterial infections.

Authors:  J J Rahal
Journal:  Bull N Y Acad Med       Date:  1987-04

5.  Isolation of Campylobacter jejuni strains resistant to nalidixic acid and fluoroquinolones from children with diarrhea in Athens, Greece.

Authors:  S Chatzipanagiotou; E Papavasiliou; E Malamou-Lada
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-07       Impact factor: 3.267

6.  Comparative in vitro activities of selected antimicrobial agents against Edwardsiella tarda.

Authors:  J F Reinhardt; S Fowlston; J Jones; W L George
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

7.  Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulfamethoxazole for acute shigellosis in adults.

Authors:  E Gotuzzo; R A Oberhelman; C Maguiña; S J Berry; A Yi; M Guzman; R Ruiz; R Leon-Barua; R B Sack
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

Review 8.  Quinolones in the treatment of acute bacterial diarrhoeal diseases.

Authors:  H E Akalin
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms.

Authors:  R Vanhoof; J M Hubrechts; E Roebben; H J Nyssen; E Nulens; J Leger; N De Schepper
Journal:  Infection       Date:  1986 Nov-Dec       Impact factor: 3.553

10.  Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis.

Authors:  E Singlas; A M Taburet; I Landru; H Albin; J P Ryckelinck
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.